Dublin, April 24, 2020 (GLOBE NEWSWIRE) -- The "COVID-19 Update: Molecular Diagnostics, Immunoassays, Vaccines, Telehealth and Other Areas" report has been added to ResearchAndMarkets.com's offering.

For years, the analyst has covered the fields of molecular diagnostics, immunoassays, vaccines, and telehealth - these all find themselves both sought-after and challenged during the current COVID-19 crisis

This report provides trending developments, company announcements, and analysis from the analysis team on the fast-breaking events in the COVID-19 epidemic.

Particular sections address the most important market changes:

Molecular Diagnostics: It's important to note that the entire molecular testing concept originated in the midst of a crisis, at that time of the AIDS crisis, and has since been brought to bear on a number of emerging and mature infectious disease categories. COVID-19 has seen the molecular in vitro diagnostics (IVD) industry bring out its best efforts in terms of fast test RT-PCR tests for their systems, point of care solutions, syndromic tests, high throughput systems and surge production on badly needed kits.

Immunoassays: Never have immunoassays been of such worldwide attention, as antibody tests are greatly sought. With this, come concerns about accuracy levels on broad populations and greater knowledge about development times. There are now immunoassays in development. We track these efforts and provide commentary on the role of these tests in a threat so far dominated by molecular diagnostics.

Vaccines: The analyst look at the vaccines in development and the struggles with vaccine discovery and manufacturing in other pandemics. Companies developing vaccines are featured.

Other Traditional IVDs: With many hospitals shut down across the globe, what is the impact and expected future of standard in vitro diagnostic testing? - from company statements made both publicly and directly to the analyst.

Remote Patient Monitoring: Already a healthcare trend that was catching on but perhaps struggling to convince payors of its critical necessity, remote patient monitoring, and telehealth transformed overnight with social distancing policies and relaxed HIPAA rules. But will market players be crowded out by traditional phone and web video companies?

This report does not seek to provide a data-driven market assessment due to the rapidly-changing situation but does provide analyst commentary that may assist customers needing to work out models. Some of the market estimates provide foundational bases on which to judge potential market impact. Commentary and analysis from the analysts who have studied markets in some cases for decades add understanding to the current, often chaotic, market atmosphere. Further publications and surveys from the analyst will provide additional market impact data.

No one company has the solution to COVID-19. Multiple companies have solutions to one problem or part of the solution, and companies are partnering to build strength and distribute products.

Key Topics Covered

Chapter One: SARS-Cov-2 Recent Developments

Chapter Two: Molecular Diagnostics and SARS-Cov-2

Chapter Three: Bottlenecks

Chapter Four: Covid-19 Immunoassays

Chapter Five: Other Test Categories Impact: Critical Care, Chemistries

Chapter Six: Vaccines and SARS-Cov-2

Chapter Seven: Boost for Remote Patient Monitoring Seen in SARS-Cov-2 Crisis

Chapter Eight: a Role for Artificial Intelligence (AI)

Chapter Nine: Therapeutics and Covid-19

Chapter Ten: Respiratory Equipment in Extreme Demand

Chapter Eleven: Research Laboratory Operations Impacted

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/1anzkz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. 

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900